Skip to content
naulon

Not checkedNot checked for notices yet.

Minimum effective maintenance omalizumab dose for chronic spontaneous urticaria in an 11 year old girl

Adolfo n Blanco

World Allergy Organization Journal · 2020

doi:10.1016/j.waojou.2020.100229 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Dramatic response to Omalizumab in a girl with severe Chronic Spontaneous Urticaria (CSU) and identification of the minimum effective maintenance dose. An otherwise healthy 11-year-old girl began at 8 months of age with a CSU, in the last 3 years did not respond to antihistamine maximum doses and at presentation had serious adverse effects from prolonged corticosteroid therapy as; Cushing syndrome, obesity with body mass index (BMI) of 27, posterior subcapsular cataract in the right eye and biochemical diagnosis of suppression of the hypothalamic-pituitary-axis (HPA). Had negative tioperoxidase and thyroglobulin autoantibodies and normal thyroid function. IgE levels (400mU/l). Negative Parasitological assay. Normal Red, white cells, differential and platelets. Normal liver and kidney functions. Negative autologous serum skin test. Urticaria activity score of 7 days (UAS7) of 42. Omalizumab in a dose of 300mg every month is started achieving complete resolution of Urticaria in 30 days. Complete withdrawal from glucocorticosteroid therapy is accomplished in seven months after complete recovery of the HPA. After one year of treatment and due to lack of stock of Omalizumab thereafter receives 300mg every 45 days for 3 doses with complete absence of urticarial lesions. Due to the same drawback thereafter received 300 mg every 60 days for 3 doses. Urticarial lesions appeared systematically 48 to 50 days after the 300mg Omalizumab dose. Complete resolution of the lesions occurred when placed again on Omalizumab 300mg every 30 days. One year later on, owing to Omalizumab supply difficulties, she started to receive 150 mg every 30 days. Remained asymptomatic during 5 doses and thereafter urticarial lesions recurred at days 25 or 28 post 150mg doses. Thereafter remained on 300mg every 45 days with excellent response until present time. Currently completed 42 months of treatment without showing any adverse reaction to omalizumab, with complete resolution of posterior subcapsular cataract and achieved a BMI of 18. Any attempt to stop therapy provoked Urticarial lesions. We describe a severe case of CSU in an 11-year-old girl with a complete response to Omalizumab. Due to the high cost of this drug we suffer a lack of provision at different times. The inconvenience urged us to determine the minimum effective dose of Omalizumab for the CSU of this patient. 300mg of Omalizumab every 45 days offers complete control of the disease.

Abstract licence: CC BY-NC-ND

References2

    2 more references, whose wording the paper’s licence keeps private.

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.